Aptinyx Inc., a biotechnology firm developing small molecules that modulate the NMDA receptor to treat neurological disorders, closed a $65m Series A round, capitalizing on the cache that its management team gained from the sale of Naurex Inc. to Allergan PLC.
Evanston, Illinois-based Aptinyx will use its Series A cash to begin a Phase I clinical trial for its first drug...